SirTlab Corporation

Company Overview

Snapshot

Founded in January 2012 by Boaz Misholi, SirTlab Corporation operates with 1–10 employees. The company has raised $1.53M across three funding rounds. In May 2025, SirTlab Corporation secured funding from PipelBiz.

Business overview

SirTlab Corporation is a Health Tech & Life Sciences company focused on developing genetic treatments for age-related diseases, particularly severe liver conditions. The company's core technology centers on restoring SIRT6 expression using a patented SIRT6-mRNA-LNP2 platform, which is designed for liver-specific expression. SirTlab Corporation serves the pharmaceutical and healthcare industries, targeting chronic patients globally with its therapeutics and pharmaceuticals.

Strategic signal

In June 2022, SirTlab Corporation appointed Michael G. Kauffman, MD, PhD, as Co-Chairman of the Board of Directors and Chief Medical Officer. This strategic leadership addition signals a strengthening of the company's medical and scientific expertise, which is crucial for advancing its genetic treatment pipeline and navigating clinical development in the competitive therapeutics market.

Company Intelligence Q&A

What is SirTlab Corporation's primary focus?

SirTlab Corporation is focused on developing genetic treatments for age-related diseases, with a particular emphasis on restoring SIRT6 expression for severe liver diseases and other conditions of aging.

When was SirTlab Corporation founded?

SirTlab Corporation was founded in January 2012.

Who is the founder of SirTlab Corporation?

Boaz Misholi is the founder of SirTlab Corporation.

What was a significant leadership appointment at SirTlab Corporation?

In June 2022, SirTlab Corporation appointed Michael G. Kauffman, MD, PhD, as Co-Chairman of the Board of Directors and Chief Medical Officer, enhancing its medical and scientific leadership.